![BDR Pharma ties up Eli Lilly for COVID-19 drug](https://www.thehindu.com/static/theme/default/base/img/og-image.jpg)
BDR Pharma ties up Eli Lilly for COVID-19 drug
The Hindu
Generic drugmaker BDR Pharma has entered into a royalty-free, limited and non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacturing and distribution of Baricitinib,
Generic drugmaker BDR Pharma has entered into a royalty-free, limited and non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacturing and distribution of Baricitinib, a repurposed drug indicated in the treatment of COVID-19. The collaboration will increase the availability of baricitinib in the country, a release from BDR Pharma said. The company has applied for restricted emergency use approval with the Drugs Controller General of India for baricitinib for COVID-19. Chairman Dharmesh Shah sought to underscore the need to accelerate and harmonise production of drugs indicated in the treatment of COVID-19.More Related News